Key result
ACE inhibitors, estrogen hormone replacement therapy, metformin in diabetic patients, and pravastatin appear to beneficially reduce the production of plasminogen activator inhibitor-1.
Why the study?
Do common pharmacologic agents such as ACE inhibitors, estrogen, metformin, and statins reduce PAI-1 production?
Do common pharmacologic agents such as ACE inhibitors, estrogen, metformin, and statins reduce PAI-1 production?
This review highlights that certain common medications, including ACE inhibitors, estrogen, metformin, and pravastatin, may offer cardiovascular benefits by reducing PAI-1 levels and improving endogenous thrombolysis.
Answers are grounded in this paper and cite their sources.
May support PAI-1 reduction by common agents; hypothesis-generating and should not yet change practice.
Plasminogen activator inhibitor-1 (PAI-1) is the major inhibitor of endogenous thrombolysis, thereby promoting thrombosis. PAI-1 is also a primary contributor to the development and recurrence of acute myocardial infarction. The renin angiotensin system, hypertriglyceridemia, hyperglycemia and hyperinsulinemia, and estrogen all influence the fibrinolytic system and PAI-1 in particular. Available data strongly suggest that angiotensin-converting enzyme (ACE) inhibitors and hormone replacement therapy with estrogen beneficially reduce PAI-1 production. Metformin, an agent commonly used for non-insulin-dependent diabetes mellitus (NIDDM), appears to favorably decrease PAI-1 production in NIDDM patients but not nondiabetic patients. Among the cholesterol-lowering statins, clinical literature evaluating pravastatin provides the most compelling data to support this agent's favorable effect on PAI-1. Other available statins either have not displayed an effect on PAI-1 or do not have clear data to conclusively define their effects on the fibrinolytic system.
No takes yet. Share an insight, caveat, or question.
Tsikouris et al. (2002) conducted a review in Thrombosis and acute myocardial infarction. Pharmacologic agents (ACE inhibitors, estrogen, metformin, statins) was evaluated on Plasminogen activator inhibitor-1 (PAI-1) production. ACE inhibitors, estrogen hormone replacement therapy, metformin in diabetic patients, and pravastatin appear to beneficially reduce the production of plasminogen activator inhibitor-1.
Synapse has enriched 10 related papers. Consider them for comparative context: